Results 91 to 100 of about 1,712,061 (282)

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi   +5 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

Cannabinoids for the treatment of chronic refractory pruritus

open access: yesJournal of Dermatological Treatment, 2019
SirThe use and acceptance of medicinal marijuana has expanded, with a growing number of states passing legislature in favor of comprehensive cannabis programs (1).
Raveena Khanna   +3 more
openaire   +2 more sources

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

open access: yesEpilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee   +20 more
wiley   +1 more source

Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study

open access: yesDermatology and Therapy
Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of
Svenja Royeck   +7 more
doaj   +1 more source

Monitoring and Mitigation Strategies for Hazardous Compounds in Chinese Rice Wine (Huangjiu): A Comprehensive Review

open access: yesFood Safety and Health, EarlyView.
This review elucidates the formation pathways and detection technologies for ethyl carbamate, biogenic amines, and higher alcohols in Huangjiu. It concludes that integrated control frameworks are essential to decouple safety risks from the metabolic processes responsible for flavor development.
Lulu Liu   +5 more
wiley   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell   +11 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Combined radiofrequency and topical exosomes in atrophic vulvar lichen sclerosus: A case report

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Vulvar lichen sclerosus (VLS) is a chronic inflammatory dermatological‐gynecological condition. Conventional first‐line treatment comprises topical corticosteroids; however, many patients remain refractory. Energy‐based devices, including radiofrequency (RF), have shown promising results in VLS, with symptomatic and functional improvement ...
Luisa Mendonca de Oliveira   +3 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Home - About - Disclaimer - Privacy